Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther ADR (NQ: ADAP )

1.090 +0.030 (+2.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 454,026
Open 1.080
Bid (Size) 1.070 (46)
Ask (Size) 1.150 (43)
Prev. Close 1.060
Today's Range 1.050 - 1.110
52wk Range 1.010 - 2.650
Shares Outstanding 991,831,158
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –
From Brodsky & Smith LLC
Via Globe NewsWire
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
 
Via Benzinga

Performance

YTD
-34.73%
-34.73%
1 Month
-33.94%
-33.94%
3 Month
-25.34%
-25.34%
6 Month
+1.40%
+1.40%
1 Year
-47.09%
-47.09%

More News

Read More
Why Is TCR2 Therapeutics Stock Trading Higher Today?
Via Benzinga
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Via Benzinga
Adaptimmune Therapeutics's Earnings Outlook
Via Benzinga
Expert Ratings for Adaptimmune Therapeutics
Via Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
Via Spotlight Growth
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
Via InvestorPlace
ADAP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adaptimmune Therapeutics plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
Via Newsfile
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
Via Newsfile
Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023
Via Newsfile
Adaptimmune Announces Changes to Board of Directors
Via Newsfile
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
Via Newsfile
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma
Via Newsfile
Exposures Product Safety
Credit Suisse, Autodesk And Other Big Losers From Wednesday
Via Benzinga
Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent
Via Newsfile
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.